Ontario's Significant Investment in Piramal Pharma Enhances Life Sciences Innovation and Job Creation

Ontario's Strategic Investment in Piramal Pharma

On September 29, 2026, the Ontario government revealed a significant investment of $1,753,620 aimed at fostering innovation in the life sciences sector through Piramal Pharma Solutions' Aurora facility. This initiative, supported by the Life Sciences Scale-Up Fund (LSSUF), is part of a broader strategy to enhance the province's healthcare innovation and solidify its leadership in the life sciences industry.

Piramal Pharma Solutions (PPS), a prominent global Contract Development and Manufacturing Organization (CDMO), plans to deploy the funds to upgrade its infrastructure, which will facilitate the commercialization of Ontario-made health technologies. This upgrade is not merely a financial investment; it represents a commitment to better serve the healthcare sector by producing critical drug substances and improving the region's biomanufacturing capabilities.

Job Creation and Economic Growth

The investment is projected to create 12 new positions while preserving 183 existing jobs, ensuring a stable workforce as the company expands its capabilities. This is not just about numbers; it's about unlocking new market opportunities and enhancing the competitiveness of Ontario’s life sciences sector in an ever-evolving global landscape.

Peter DeYoung, CEO of Piramal Global Pharma, expressed gratitude toward the Ontario government and MPP Dawn Gallagher Murphy for their support. He stated, "This funding will help enable Piramal Pharma Solutions to upgrade our site infrastructure, strengthen our manufacturing capabilities, and enhance our ability to serve patients and customers around the world."

The investment will further underpin projects focusing on sustainability, operational efficiency, and modernization of the facility—key areas that are becoming increasingly critical in today's manufacturing environment.

Supporting Ontario’s Life Sciences Strategy

Dawn Gallagher Murphy, a Member of Provincial Parliament for Newmarket—Aurora, emphasized the importance of this funding in fostering innovation. She stated, "Through the Life Sciences Scale-Up Fund, our government is ensuring that Ontario businesses are positioned to develop, commercialize, and deploy new technologies across the health-care system."

The LSSUF, launched in 2024 with an initial budget of $24 million, is an integral part of Ontario's Life Sciences Strategy, which aims to position the province as a global leader in health innovation. The 2026 Ontario budget further allocated an additional $24 million to promote the adoption of innovative healthcare technologies, demonstrating the government's commitment to supporting local companies.

A Vision for the Future

Vic Fedeli, Ontario's Minister of Economic Development, Job Creation, and Trade, remarked on the critical role the life sciences sector plays in the province's economy. He highlighted that investing in Piramal through the LSSUF is not just about immediate economic gains; it’s about laying the groundwork for future generations of innovative healthcare solutions. "Ontario's life sciences sector plays a critical role in supporting the discovery and development of innovative medicines and technologies," Fedeli noted.

By backing the Aurora site, the Ontario government is reinforcing the province’s position as a leader in the life sciences field, helping Piramal Pharma advance next-generation technologies that will ultimately benefit patients globally.

About Piramal Pharma Solutions

Piramal Pharma Solutions offers a comprehensive range of services across the drug development lifecycle, serving clients through a globally integrated network in North America, Europe, and Asia. The organization specializes in drug discovery, process and pharmaceutical development, commercial supply, and biologics, including vaccines and gene therapies. This positions them uniquely to respond to global healthcare needs effectively.

For more details, you can visit Piramal Pharma Solutions. This investment marks a pivotal moment for both Piramal Pharma and Ontario's healthcare landscape, setting a course for innovation and sustainability in the years ahead.